A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
Blood. 2021 Nov 25;138(21):2031-2041. doi: 10.1182/blood.2020009984.
Blood. 2021.
PMID: 34407542
Clinical Trial.